scholarly journals Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions

2003 ◽  
Vol 49 (11) ◽  
pp. 1785-1796 ◽  
Author(s):  
Santica M Marcovina ◽  
Marlys L Koschinsky ◽  
John J Albers ◽  
Sonia Skarlatos
Keyword(s):  
Structural Complexity ◽  
Lipoprotein A ◽  
Blood Institute ◽  
Relative Contribution ◽  
National Heart ◽  
The Us ◽  
National Heart Lung ◽  
Artery Disease ◽  
Underlying Mechanisms ◽  
Size Heterogeneity

Abstract It has been estimated that ∼37% of the US population judged to be at high risk for developing coronary artery disease (CAD), based on the National Cholesterol Education Program guidelines, have increased plasma lipoprotein(a) [Lp(a)], whereas Lp(a) is increased in only 14% of those judged to be at low risk. Therefore, the importance of establishing a better understanding of the relative contribution of Lp(a) to the risk burden for CAD and other forms of vascular disease, as well as the underlying mechanisms, is clearly evident. However, the structural complexity and size heterogeneity of Lp(a) have hindered the development of immunoassays to accurately measure Lp(a) concentrations in plasma. The large intermethod variation in Lp(a) values has made it difficult to compare data from different clinical studies and to achieve a uniform interpretation of clinical data. A workshop was recently convened by the National Heart, Lung, and Blood Institute (NHLBI) to evaluate our current understanding of Lp(a) as a risk factor for atherosclerotic disorders; to determine how future studies could be designed to more clearly define the extent to which, and mechanisms by which, Lp(a) participates in these processes; and to present the results of the NHLBI-supported program for the evaluation and standardization of Lp(a) immunoassays. This report includes the most recent data presented by the workshop participants and the resulting practical and research recommendations.

The interagency strategic plan for research and development of blood products and related technologies for trauma care and emergency preparedness 2015-2020

2018 ◽  
Vol 13 (3) ◽  
pp. 181-194 ◽  
Author(s):  
Anthony E. Pusateri, PhD ◽  
Mary J. Homer, PhD ◽  
Todd E. Rasmussen, MD ◽  
Kevin R. Kupferer, DHSc ◽  
W. Keith Hoots, MD
Keyword(s):  
Research And Development ◽  
Trauma Care ◽  
New Technologies ◽  
Strategic Plan ◽  
Blood Products ◽  
Blood Institute ◽  
National Heart ◽  
Combat Casualty ◽  
The Us ◽  
National Heart Lung

Intensive blood use is expected to occur at levels, which will overwhelm blood supplies as they exist with current capabilities and technologies, both in civilian mass casualty events and military battlefield trauma. New technologies are needed for trauma care, and specifically to provide safer, more effective, and more logistically supportable blood products to treat patients with, or at risk of developing, acquired bleeding disorders resulting from trauma, acute radiation exposure, or other causes. Three of the primary agencies with major research and development programs related to blood products, the Biomedical Advanced Research and Development Authority (BARDA), the Department of Defense (DoD), and the National Heart, Lung, and Blood Institute are uniquely positioned to partner in addressing these issues, which have significant implications for each respective agency, as well as for the US population. Providing leadership, coordination, and oversight for the Food and Drug Administration’s national and global health security, counterterrorism, and emerging threats portfolios, the US Food and Drug Administration Office of Counterterrorism and Emerging Threats serves in a critical advisory and facilitative role regarding development and availability of blood products. This plan is informed by the 2012 PHEMCE Strategy (US Department of Health and Human Services, 2012), the 2007 “Shaping the Future of Research” Strategic Plan for the National Heart, Lung, and Blood Institute, the 2011 BARDA Strategic Plan, the DoD Combat Casualty Care Research Program: Policy Review, the 2015 DoD Hemorrhage and Resuscitation Research and Development Strategic Plan, and more than 30 participants from other agencies who participated in planning.

Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop

2021 ◽  
Vol 14 (6) ◽  
Author(s):  
Jane A. Leopold ◽  
Steven M. Kawut ◽  
Micheala A. Aldred ◽  
Stephen L. Archer ◽  
Ray L. Benza ◽  
...  
Keyword(s):  
Vascular Diseases ◽  
Right Ventricular Dysfunction ◽  
Right Heart Failure ◽  
Pulmonary Vascular Disease ◽  
Blood Institute ◽  
National Heart ◽  
National Heart Lung ◽  
Underlying Mechanisms ◽  
The Right

Right ventricular dysfunction is a hallmark of advanced pulmonary vascular, lung parenchymal, and left heart disease, yet the underlying mechanisms that govern (mal)adaptation remain incompletely characterized. Owing to the knowledge gaps in our understanding of the right ventricle (RV) in health and disease, the National Heart, Lung, and Blood Institute commissioned a working group to identify current challenges in the field. These included a need to define and standardize normal RV structure and function in populations; access to RV tissue for research purposes and the development of complex experimental platforms that recapitulate the in vivo environment; and the advancement of imaging and invasive methodologies to study the RV within basic, translational, and clinical research programs. Specific recommendations were provided, including a call to incorporate precision medicine and innovations in prognosis, diagnosis, and novel RV therapeutics for patients with pulmonary vascular disease.

Sign in / Sign up

Export Citation Format

Share Document